Abbot India recently executed a significant block trade of approximately INR 22 crore, involving 8,064 shares priced at INR 27,715 each on the NSE.

Seven companies, including Abbott India, Torrent Pharma, and Sun Pharma, have announced their dividend record dates. This means shareholders of these companies will receive their dividends soon, as stated in the companies' respective announcements.

According to MarketsMojo, Abbott India's quality rating has been lowered from 'Excellent' to 'Good' due to mixed financial performance. The recommendation for the company has also changed from 'Hold' to 'Sell'.

Abbott India reported a 10% increase in Q4 EBITDA, reaching INR 4.8 billion, accompanied by an improvement in the profit margin to 28.1%.

Abbott India reported a 10% year-over-year increase in Q4 profit, amounting to Rs 394.93 crore. Despite this growth, the company's shares experienced a 2% dip, closing at Rs 27224.40, possibly due to market fluctuations or other factors. The full-year net profit for FY26 rose by 9.7%, reaching Rs 1552 crore.

Abbott India has announced that shareholders must own the company's stocks by July 24, 2026, to be eligible for the final dividend, pending approval at the AGM. The dividend payment is scheduled to occur on or after August 18, 2026.

Abbott India announced a dividend of INR 656 per share for FY26, consisting of a final dividend of INR 525 and a special dividend of INR 131. This move comes as the stock was previously traded at INR 27,776.95 on BSE.

Abbott India demonstrates a robust performance this week, surging by 4.86%, significantly outpacing the Sensex's 1.25% growth. This momentum appears to be fueled by a technical shift, revaluation of its worth, and an upgrade in its Mojo grade to 'Hold'.

Abbott India will announce its FY26 results and decide on a potential final dividend during a board meeting on May 11, 2026. The trading window is currently closed from April 1 to May 13 due to insider trading regulations.

Abbott India has announced significant management shifts: Anisha Motwani's tenure ends in April 2026, while Alison Davies steps down on the same date. New appointments include Neeraj Jain and James Wenner as Independent and Non-Executive Directors. Amol Metkar is set to assume the role of Goa Plant Director from June 1, 2026.

Abbott India's shares dropped to a 52-week low on April 13th, despite the Sensex gaining 2.33% that week. Analysts have now downgraded the stock from 'Hold' to 'Sell', advising investors to reconsider their holdings.

JPMorgan has lowered its outlook for Abbott India due to concerns about the company's growth, now categorizing it as 'Neutral'. The revised target suggests a more cautious view on the company's potential returns.

JPMorgan has reduced its stance on Abbott India to neutral and lowered the price target by nearly 20%, due to growth concerns. However, Abbott's collaboration with Novo Nordisk for semaglutide marketing has helped the stock rise 1.2% today, despite a 10% decrease year-to-date in 2026.